UNIGE document Scientific Article - Review
previous document  unige:34829  next document
add to browser collection

Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism

Goldhaber, Samuel Z
Published in European heart journal. 2014, vol. 35, no. 28, p. 1836-1843
Abstract Direct oral anticoagulants (DOACs) specifically target factor IIa or Xa and represent a major step forward in the treatment of acute- and long-term prevention of venous thrombo-embolism (VTE). They are at least as effective and as safe as conventional therapy (heparins and vitamin-K inhibitors) and have practical advantages, such as fixed dosing and no need for laboratory monitoring. These antithrombotic agents introduce a new paradigm for the day-to-day management of VTE. Direct oral anticoagulants should streamline the management of most patients with VTE and will facilitate care in the outpatient setting. Nevertheless, it remains uncertain how to select specific DOACs for particular profiles of patients, and the optimal management of bleeding complications is evolving.
PMID: 24510637
Full text
Article (Published version) (309 Kb) - public document Free access
Research groups Geneva Platelet Group (13)
La maladie thromboembolique veineuse (808)
(ISO format)
FONTANA, Pierre, GOLDHABER, Samuel Z, BOUNAMEAUX, Henri. Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism. In: European Heart Journal, 2014, vol. 35, n° 28, p. 1836-1843. doi: 10.1093/eurheartj/ehu027 https://archive-ouverte.unige.ch/unige:34829

510 hits



Deposited on : 2014-03-18

Export document
Format :
Citation style :